Trial · NCT03819153
Trial comparisons13
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 13 of 13
Download this page as JSON| Comparison | Source |
|---|---|
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to Occurrence of Initiation of Chronic Renal Replacement Therapy | Trial comparisons |
Semaglutide vs Placebo: Number of Participants From Time of Randomization to Time to First Occurrence of a Major Adverse Cardiovascular Event (MACE): Acute Myocardial Infarction (Non Fatal); Non-fatal Stroke; and CV Death | Trial comparisons |
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to Occurrence of CV Death | Trial comparisons |
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to Occurrence of Onset of Persistent ≥50% Reduction in eGFR (CKD-EPI) | Trial comparisons |
Semaglutide vs Placebo: Number of Participants From Time of Randomization to Time to First Occurrence of Major Adverse Limb Events (MALE): Acute Limb Ischaemia Hospitalization and Chronic Limb Ischaemia Hospitalization | Trial comparisons |
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to Occurrence of Renal Death | Trial comparisons |
Semaglutide vs Placebo: Number of Participants From Time of Randomization to Time to Occurrence of Each of the Individual Components of the Confirmatory Secondary MACE Endpoint: Non-fatal Myocardial Infarction | Trial comparisons |
Semaglutide vs Placebo: Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death | Trial comparisons |
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to Occurrence of Onset of Persistent eGFR (CKD-EPI) <15mL/Min/1.73m^2 | Trial comparisons |
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to Time to Occurrence of Each of the Individual Components of the Confirmatory Secondary MACE Endpoint: Non-fatal Stroke | Trial comparisons |
| Semaglutide vs Placebo: Number of Participants From Time of Randomization to Time to Occurrence of All-cause Death | Trial comparisons |
| Semaglutide vs Placebo: deaths from any cause | Trial comparisons |
| Semaglutide vs Placebo: serious adverse events | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03819153/comparisons